Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), featuring a year-to-date gain of 71.49% and upside potential of 68.70%, secures a spot on our list of hot biotech stocks under $5 to buy.
A busy period of pipeline and platform news has kept the clinical-stage antibody drug conjugate (ADC) company in focus, with fresh data at a major oncology conference arriving alongside a deal that extends its program runway.
A more recent development came at ASCO 2026, where Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) presented a real-world analysis on May 30, 2026, supporting the therapeutic potential of targeting seizure-related homolog protein 6 with its next-generation ADC HWK-206 for the treatment of neuroendocrine tumors, including small cell lung cancer.
The analysis, conducted in collaboration with Tempus AI, showed SEZ6 demonstrates consistently high expression across disease stages and metastatic settings in SCLC, as well as enrichment in neuroendocrine-high SCLC subtypes. HWK-206 uses a biparatopic approach designed to potentially improve binding and internalization. An IND application for HWK-206 in SCLC and neuroendocrine tumors is expected to be submitted in mid-2026, with a Phase 1 start planned for the third quarter of 2026.
That followed a pipeline expansion announced on May 21, 2026, when Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) entered an option agreement with Hangzhou DAC for access to the CPT113 linker-payload technology for use in up to five additional ADC programs, including dual-payload variations.
Under the agreement, Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) retains global rights and full program control, and anticipates submitting IND applications for multiple new programs over the next 12 to 24 months. Phase 1 dose-escalation trials for HWK-007 and HWK-016 are currently enrolling, with data expected in the first half of 2027.
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) is a preclinical oncology company developing next-generation antibody-drug conjugates targeting PTK7, MUC16, and SEZ6, aiming to improve treatment outcomes for patients with difficult-to-treat cancers.
While we acknowledge the risk and potential of WHWK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than WHWK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
